Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC)

Inclusion Criteria: * Written informed consent according to Swiss law and ICH GCP E6 regulations before registration and prior to any trial specific procedures; * Histologically or cytologically confirmed diagnosis of NSCLC (adeno-, squamous-, large cell carcinoma or NSCLC not otherwise specified); * Patients planned for systemic first-line therapy with a combination of a carboplatin-based doublet chemotherapy and a PD-1 / PD-L1 targeting immune checkpoint inhibitor; * Patients not eligible for immune checkpoint inhibitor monotherapy irrespective of PD-L1 expression; * Locally advanced unresectable stage III or metastatic stage IV disease (defined as TNM, according to 8th edition) not eligible for curative surgery and/or definitive (curative intended) chemoradiotherapy; * No sensitizing EGFR mutation, METex14 skipping mutation, BRAF V600E mutation, ALK/ROS1/RET, NTRK1/2 gene rearrangements, HER2 mutations, amplifications detected in primary tumor or metastases; * Have not received prior systemic treatment for their metastatic NSCLC. Patients who received adjuvant, neoadjuvant chemotherapy or chemoradiotherapy with curative intent for nonmetastatic disease are eligible if the therapy was completed at least 12 months prior to the diagnosis of metastatic disease; * Patients with treated and stable CNS metastases are eligible, provided they meet the following criteria: * No ongoing requirement for corticosteroids as therapy for CNS disease; anticonvulsants at a stable dose al…